Identification/NN
of/IN
a/DT
human/JJ
LIM-Hox/NN
gene/NN
,/,
hLH-2/NN
,/,
aberrantly/RB
expressed/VBN
in/IN
chronic/JJ
myelogenous/JJ
leukaemia/NN
and/CC
located/JJ
on/IN
9q33-34.1/NN
./.

We/PRP
describe/VBP
the/DT
isolation/NN
of/IN
human/JJ
LH-2/NN
,/,
a/DT
putative/JJ
transcription/NN
factor/NN
containing/VBG
two/CD
cysteine-rich/JJ
regions/NNS
(/(
LIM/NN
domains/NNS
)/)
and/CC
a/DT
homeobox/NN
(/(
Hox/NN
)/)
DNA-binding/JJ
domain/NN
./.
=====
High/JJ
levels/NNS
of/IN
hLH-2/NN
expression/NN
were/VBD
observed/VBN
in/IN
all/DT
cases/NNS
of/IN
chronic/JJ
myelogenous/JJ
leukaemia/NN
(/(
CML/NN
)/)
tested/VBN
,/,
regardless/RB
of/IN
disease/NN
status/NN
./.
=====
hLH-2/NN
was/VBD
mapped/VBN
to/TO
chromosome/NN
9Q33-34.1/NN
,/,
in/IN
the/DT
same/JJ
region/NN
as/IN
the/DT
reciprocal/JJ
translocation/NN
that/WDT
creates/VBZ
the/DT
BCR-ABL/NN
chimera/NN
of/IN
the/DT
Philadelphia/NN
chromosome/NN
(/(
Ph/NN
'/''
)/)
,/,
the/DT
hallmark/NN
of/IN
CML/NN
;/:
hLH-2/NN
was/VBD
retained/VBN
on/IN
the/DT
derivative/JJ
9/CD
chromosome/NN
and/CC
is/VBZ
therefore/RB
centromeric/JJ
of/IN
c-ABL/NN
./.
=====
The/DT
proximity/NN
of/IN
hLH-2/NN
to/TO
the/DT
breakpoint/NN
on/IN
chromosome/NN
9/CD
raises/VBZ
the/DT
possibility/NN
of/IN
cis-activation/NN
by/IN
the/DT
t(9;22)(q34;q11)/NN
translocation/NN
./.
=====
In/IN
addition/NN
to/TO
finding/VBG
hLH-2/NN
expression/NN
in/IN
all/DT
cases/NNS
of/IN
CML/NN
,/,
expression/NN
was/VBD
observed/VBN
in/IN
lymphoid/JJ
malignancies/NNS
and/CC
myeloid/JJ
cell/NN
lines/NNS
,/,
but/CC
not/RB
in/IN
primary/JJ
cases/NNS
of/IN
acute/JJ
myelogenous/JJ
leukaemia/NN
./.
=====
The/DT
role/NN
of/IN
hLH-2/NN
in/IN
the/DT
development/NN
or/CC
progression/NN
of/IN
leukaemia/NN
is/VBZ
not/RB
known/VBN
./.
=====
However/RB
,/,
hLH-2/NN
may/MD
prove/VB
useful/JJ
as/IN
a/DT
marker/NN
of/IN
CML/NN
for/IN
monitoring/VBG
residual/JJ
disease/NN
./.